Palvella's QTORIN™ Shows Highly Positive Phase 3 & 2 Data for Rare Vascular Malformations, NDA Filing on Track for H2 2026
PVLA has more than doubled off its 52-week low of $20.2.
Summary
Palvella Therapeutics announced highly positive new clinical data from its Phase 3 SELVA and Phase 2 TOIVA studies for QTORIN™ rapamycin, presented at the ISSVA World Congress. The Phase 3 SELVA data showed 100% of participants aged 6-11 years were rated "Much Improved" or "Very Much Improved" on the mLM-IGA scale, with statistically significant improvements in leaking/bleeding. The Phase 2 TOIVA study also demonstrated significant improvements. This robust data supports QTORIN™ rapamycin as a potential first-in-disease therapy for serious, rare vascular malformations, where no FDA-approved treatments currently exist. The company reiterated its plan to file an NDA in the second half of 2026, targeting potential approval in the first half of 2027. This strong clinical validation significantly de-risks the program and is a major positive catalyst for the company, highlighting its potential to address a significant unmet medical need.
At the time of this announcement, PVLA was trading at $115.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $20.20 to $151.18. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.